{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-001172","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.768958+00:00","generated_at":"2026-06-18T21:42:23.375260+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sunshine Biopharma signs exclusive worldwide license with U. Arizona for PLpro COVID-19 treatment","bullets":["License grants exclusive worldwide rights to PLpro protease inhibitors of SARS-CoV-2 (COVID-19).","Company pays 3% royalty on net sales and 30% of sublicensee revenues.","Milestone payments required; University can terminate if milestones not met.","Collaboration began February 2022; option to license was exercised."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-001172","json":"https://secwatch.observer/filing/0001683168-23-001172.json","markdown":"https://secwatch.observer/filing/0001683168-23-001172.md","text":"https://secwatch.observer/filing/0001683168-23-001172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/0001683168-23-001172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:42:23.375260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cd1e91c5891ed5db0dc1d5eea1d3cbbd47b7ee4","claim":"Sunshine Biopharma Inc. entered into Exclusive Patent License Agreement with Arizona Board of Regents on behalf of the University of Arizona (effective 2023-02-24).","evidence_excerpt":"On February 24, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into an Exclusive Patent License Agreement (the “License Agreement”) with Arizona Board of Regents on behalf of the University of Arizona (the “University”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/0001683168-23-001172-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Arizona Board of Regents on behalf of the University of Arizona"},{"label":"Effective","value":"2023-02-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}